@article {7053,
	title = {Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)},
	journal = {Leukemia and Lymphoma},
	volume = {57},
	year = {2016},
	note = {Cited By :1Export Date: 18 February 2017References: Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2014) Leukemia, 28, pp. 1122-1128;Dimopoulos, M.A., Richardson, P.G., Moreau, P., Current treatment landscape for relapsed and/or refractory multiple myeloma (2015) Nat Rev Clin Oncol, 12, pp. 42-54; 
Pulte, D., Jansen, L., Castro, F.A., Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century (2015) Br J Haematol, 171, pp. 189-196; 
Kumar, S.K., Lee, J.H., Lahuerta, J.J., Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study (2012) Leukemia, 26, pp. 149-157; 
Boland, E., Eiser, C., Ezaydi, Y., Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life (2013) J Pain Symptom Manage, 46, pp. 671-680; 
Molassiotis, A., Wilson, B., Blair, S., Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners (2011) Psychooncology, 20, pp. 88-97; 
Mols, F., Oerlemans, S., Vos, A.H., Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry (2012) Eur J Haematol, 89, pp. 311-319; 
Poulos, A.R., Gertz, M.A., Pankratz, V.S., Pain, mood disturbance, and quality of life in patients with multiple myeloma (2001) Oncol Nurs Forum, 28, pp. 1163-1171; 
Lacy, M.Q., Hayman, S.R., Gertz, M.A., Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma (2009) J Clin Oncol, 27, pp. 5008-5014; 
Lacy, M.Q., Hayman, S.R., Gertz, M.A., Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) (2010) Leukemia, 24, pp. 1934-1939; 
Richardson, P.G., Siegel, D.S., Vij, R., Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study (2014) Blood, 123, pp. 1826-1832; 
Leleu, X., Attal, M., Arnulf, B., Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du My{\~A}{\textcopyright}lome 2009-02 (2013) Blood, 121, pp. 1968-1975; 
Miguel, J.S., Weisel, K., Moreau, P., Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial (2013) Lancet Oncol, 14, pp. 1055-1066; 
(2015) Pomalyst{\^A}{\textregistered} (pomalidomide) [prescribing information], , Summit, NJ: Celgene Corporation; 
http://www.ema.europa.euSan Miguel, J.F., Weisel, K.C., Song, K.W., Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma (2015) Haematologica, 100, pp. 1334-1339; 
Durie, B.G., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20, pp. 1467-1473; 
Anderson, J.R., Cain, K.C., Gelber, R.D., Analysis of survival by tumor response (1983) J Clin Oncol, 1, pp. 710-719; 
Gore, S.D., Fenaux, P., Santini, V., A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial (2013) Haematologica, 98, pp. 1067-1072; 
Harousseau, J.L., Dimopoulos, M.A., Wang, M., Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma (2010) Haematologica, 95, pp. 1738-1744; 
Song, K.W., Dimopoulos, M.A., Weisel, K.C., Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma (2015) Haematologica, 100, pp. e63-e67; 
Richardson, P.G., Siegel, D., Baz, R., Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib (2013) Blood, 121, pp. 1961-1967; 
Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma (2015) N Engl J Med, 372, pp. 142-152; 
San-Miguel, J.F., Hungria, V.T., Yoon, S.S., Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial (2014) Lancet Oncol, 15, pp. 1195-1206; 
http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm435339.htmNiesvizky, R., Richardson, P.G., Rajkumar, S.V., The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (2008) Br J Haematol, 143, pp. 46-53; 
Palumbo, A., Gay, F., Bringhen, S., Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma (2008) Ann Oncol, 19, pp. 1160-1165; 
Pineda-Roman, M., Zangari, M., van Rhee, F., VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma (2008) Leukemia, 22, pp. 1419-1427; 
Quach, H., Mileshkin, L., Seymour, J.F., Predicting durable remissions following thalidomide therapy for relapsed myeloma (2009) Leuk Lymphoma, 50, pp. 223-229; 
Alegre, A., Aguado, B., Giraldo, P., Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish compassionate use registry in advanced patients (2011) Int J Hematol, 93, pp. 351-360; 
Richardson, P.G., Sonneveld, P., Schuster, M., Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial (2007) Blood, 110, pp. 3557-3560; 
Hussein, M.A., Baz, R., Srkalovic, G., Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma (2006) Mayo Clin Proc, 81, pp. 889-895; 
Siegel, D.S., Martin, T., Wang, M., A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma (2012) Blood, 120, pp. 2817-2825; 
Rajkumar, S.V., Gahrton, G., Bergsagel, P.L., Approach to the treatment of multiple myeloma: a clash of philosophies (2011) Blood, 118, pp. 3205-3211; 
Weisel, K., Dimopoulos, M., Song, K.W., Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial (2015) Clin Lymphoma Myeloma Leuk, 15, pp. 519-530; 
Lonial, S., Anderson, K.C., Association of response endpoints with survival outcomes in multiple myeloma (2014) Leukemia, 28, pp. 258-268
},
	month = {2016},
	pages = {2839 - 2847},
	abstract = {Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS). Pomalidomide plus low-dose dexamethasone (POM + LoDEX) significantly extends OS in RRMM vs. high-dose dexamethasone. Survival of patients with stable disease (SD) was compared to patients with progressive disease (PD) or >= partial response (>=PR) at cycles (C) 3, 5, and 7. Among 302 patients randomized to POM + LoDEX, at C3 19.2\% achieved >= PR, 38.4\% SD, and 14.6\% PD. Patients with SD at C3 (17.4\%) and C5 (13.6\%) showed improved responses at C7. Median OS from randomization by response at C3 was 22.4 months for >= PR (n = 58, HR 0.66; 95\% CI 0.40{\textendash}1.08, p = 0.0976 vs. SD), 16.2 months for SD (n = 116), and 6.3 months for PD (n = 44, HR 3.43; 95\% CI 2.23{\textendash}5.27, p < 0.0001 vs. SD). Similar patterns were observed for C5 and C7. Results show that POM + LoDEX should be a standard treatment after lenalidomide and bortezomib, including in SD patients. {\^A}{\textcopyright} 2016 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {MM-003, multiple myeloma, pomalidomide},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84966930023\&doi=10.1080\%2f10428194.2016.1180685\&partnerID=40\&md5=1977c141c833453201ad66eed8d97517},
	author = {Moreau, P. and Weisel, K.C. and Song, K.W. and Gibson, C.J. and Saunders, O. and Sternas, L.A. and Hong, K. and Zaki, M.H. and Dimopoulos, M.A.}
}
